Novo Nordisk A/S Class B (NOVOb)

708.6
+4.3(+0.61%)
  • Volume:
    1,583,022
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    706.2 - 714.9
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0060534915
  • S/N:1772564000

NOVOb Overview

Prev. Close
704.3
Day's Range
706.2-714.9
Revenue
134.61B
Open
708.2
52 wk Range
414.5-760.9
EPS
19.99
Volume
1,583,022
Market Cap
1.61T
Dividend (Yield)
9.35
(1.33%)
Average Vol. (3m)
1,851,001
P/E Ratio
35.23
Beta
0.76
1-Year Change
70.59%
Shares Outstanding
2,280,607,268
Next Earnings Date
Feb 02, 2022
What is your sentiment on Novo Nordisk A/S Class B?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk A/S Class B Company Profile

Employees
46982
Market
Denmark

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson’s diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellBuyStrong Buy
Technical IndicatorsStrong SellSellNeutralStrong SellStrong Buy
SummaryStrong SellStrong SellSellNeutralStrong Buy
  • Consolidating nicely for leg up to 850!🌟
    0
    • Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
      1
      • Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
        0
        • bullish??
          0
          • No. Funds are selling. Time to wait to go long...
            0
        • Perfect opportunity to make short,,
          1
          • can you explain why please?
            0
          • No explaning? 🤷
            0
          • because he has no explanation. Novo nordisk is a soli long-term stock. I know a lot about opioid treatments, and methadon is changing to lipo-methadon, wich has really only one competitor on the global field. That competitor is Camurus AB with their product buvidol. I tecommend to all investors to buy and HOLD for these two companies, because there is no other options for a opioid-replacement-care, except Suboxone, and that is going to be replaced Lipo-methadon or Buvidol, at least here in Finland. Suboxone is manufactured for Indivor Inc, by Aquestive Therapeutics, if someone wants to do a little research.
            0
        • Bullish sentiment.
          0
          • Why is going so low???
            0
            • Anyone got a view on how much the Trump/US plans to reduce medical prices will affect the share price?
              0
              • Extremely bullish double bottom pattern and fibbonacci retracement with convergence of relative strenght index upwards
                0
                • Comenté hace unos meses que es un valor muy sólido, que lo veríamos pronto en 200 $ (que con el split son 40 $), pues bien, ha superado mis expectativas y está en 45 $.... me aventuro a pronosticar que cerrará el año en torno a los 50 $. Saludos
                  0
                  • Comenté hace unos meses que es un valor muy sólido, que lo veríamos pronto en 200 $ (que con el split son 40 $), pues bien, ha superado mis expectativas y está en 45 $.... me aventuro a pronosticar que cerrará el año en torno a los 50 $. Saludos
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.